The literature presents several reports of the impact of glycemic control and diabetes in the inflammatory and coagulatory response during coronavirus disease 2019 (COVID-19). Nevertheless, the long-term impact of the COVID-19 in diabetic patients is still to be explored. Therefore, we recruited 128 patients and performed a longitudinal analysis on COVID-19-associated biomarkers of patients with COVID-19, tree and 6 months after COVID-19 recovery and put into perspective the possible long-term complication generated after COVID-19. In our investigation, we failed to verify any long-term modification on inflammatory biomarkers, but detected an increase in the glycemia and glycated hemoglobin in patients without any pre-existing history or diagnosis of diabetes (non-diabetic patients). Although diabetic and non-diabetic patients presented elevated levels of glycated hemoglobin, the c-peptide test indicated a normal beta cell function in all patients.
CITATION STYLE
Alberca, R. W., Ramos, Y. Á. L., Pereira, N. Z., Beserra, D. R., Branco, A. C. C. C., Leão Orfali, R., … Sato, M. N. (2022). Long-term effects of COVID-19 in diabetic and non-diabetic patients. Frontiers in Public Health, 10, 963834. https://doi.org/10.3389/fpubh.2022.963834
Mendeley helps you to discover research relevant for your work.